Skip to content
Other

Restructuring, Settlement and Impairment Provisions

Edwards Lifesciences Restructuring, Settlement and Impairment Provisions decreased by 100.0% to $0 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $4.2M to $0.

Analysis

StatementIncome Statement
SectionOther
First reportedQ1 2022
Last reportedQ1 2026May 6, 2026
Metric ID: other_restructuring_settlement_and_impairment_provisions

Historical Data

13 periods
 Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q1 '25Q2 '25Q1 '26
Value$15.18M$15.18M$15.18M$15.18M$0$0$0$0$0$0$4.2M$4.2M$0
QoQ Change+0.0%+0.0%+0.0%-100.0%+0.0%-100.0%
YoY Change-100.0%-100.0%-100.0%-100.0%-100.0%
Range$0$15.18M
CAGR-100.0%
Avg YoY Growth-100.0%
Median YoY Growth-100.0%

Frequently Asked Questions

What is Edwards Lifesciences's restructuring, settlement and impairment provisions?
Edwards Lifesciences (EW) reported restructuring, settlement and impairment provisions of $0 in Q1 2026.
How has Edwards Lifesciences's restructuring, settlement and impairment provisions changed year-over-year?
Edwards Lifesciences's restructuring, settlement and impairment provisions decreased by 100.0% year-over-year, from $4.2M to $0.